Literature DB >> 25037055

B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies.

Moritz F Sinner1, Katherine A Stepas2, Carlee B Moser2, Bouwe P Krijthe3, Thor Aspelund4, Nona Sotoodehnia5, João D Fontes6, A Cecile J W Janssens3, Richard A Kronmal7, Jared W Magnani8, Jacqueline C Witteman3, Alanna M Chamberlain9, Steven A Lubitz10, Renate B Schnabel11, Ramachandran S Vasan12, Thomas J Wang13, Sunil K Agarwal14, David D McManus15, Oscar H Franco16, Xiaoyan Yin17, Martin G Larson6, Gregory L Burke18, Lenore J Launer19, Albert Hofman3, Daniel Levy20, John S Gottdiener21, Stefan Kääb22, David Couper23, Tamara B Harris19, Brad C Astor24, Christie M Ballantyne25, Ron C Hoogeveen26, Andrew E Arai27, Elsayed Z Soliman28, Patrick T Ellinor10, Bruno H C Stricker29, Vilmundur Gudnason4, Susan R Heckbert30, Michael J Pencina2, Emelia J Benjamin31, Alvaro Alonso32.   

Abstract

AIMS: B-type natriuretic peptide (BNP) and C-reactive protein (CRP) predict atrial fibrillation (AF) risk. However, their risk stratification abilities in the broad community remain uncertain. We sought to improve risk stratification for AF using biomarker information. METHODS AND
RESULTS: We ascertained AF incidence in 18 556 Whites and African Americans from the Atherosclerosis Risk in Communities Study (ARIC, n=10 675), Cardiovascular Health Study (CHS, n = 5043), and Framingham Heart Study (FHS, n = 2838), followed for 5 years (prediction horizon). We added BNP (ARIC/CHS: N-terminal pro-B-type natriuretic peptide; FHS: BNP), CRP, or both to a previously reported AF risk score, and assessed model calibration and predictive ability [C-statistic, integrated discrimination improvement (IDI), and net reclassification improvement (NRI)]. We replicated models in two independent European cohorts: Age, Gene/Environment Susceptibility Reykjavik Study (AGES), n = 4467; Rotterdam Study (RS), n = 3203. B-type natriuretic peptide and CRP were significantly associated with AF incidence (n = 1186): hazard ratio per 1-SD ln-transformed biomarker 1.66 [95% confidence interval (CI), 1.56-1.76], P < 0.0001 and 1.18 (95% CI, 1.11-1.25), P < 0.0001, respectively. Model calibration was sufficient (BNP, χ(2) = 17.0; CRP, χ(2) = 10.5; BNP and CRP, χ(2) = 13.1). B-type natriuretic peptide improved the C-statistic from 0.765 to 0.790, yielded an IDI of 0.027 (95% CI, 0.022-0.032), a relative IDI of 41.5%, and a continuous NRI of 0.389 (95% CI, 0.322-0.455). The predictive ability of CRP was limited (C-statistic increment 0.003). B-type natriuretic peptide consistently improved prediction in AGES and RS.
CONCLUSION: B-type natriuretic peptide, not CRP, substantially improved AF risk prediction beyond clinical factors in an independently replicated, heterogeneous population. B-type natriuretic peptide may serve as a benchmark to evaluate novel putative AF risk biomarkers. Published by Oxford University Press on behalf of the European Society of Cardiology 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  Atrial fibrillation; B-type natriuretic peptide; Biomarker; C-reactive protein; Epidemiology; Risk prediction

Mesh:

Substances:

Year:  2014        PMID: 25037055      PMCID: PMC4197895          DOI: 10.1093/europace/euu175

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  35 in total

1.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

2.  Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure.

Authors:  Borut Jug; Miran Sebestjen; Miso Sabovic; Maja Pohar; Irena Keber
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.

Authors:  Mark Richards; M Gary Nicholls; Eric A Espiner; John G Lainchbury; Richard W Troughton; John Elliott; Christopher M Frampton; Ian G Crozier; Timothy G Yandle; Robert Doughty; Stephen MacMahon; Norman Sharpe
Journal:  J Am Coll Cardiol       Date:  2005-12-15       Impact factor: 24.094

4.  Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation.

Authors:  Patrick T Ellinor; Adrian F Low; Kristen K Patton; Marisa A Shea; Calum A Macrae
Journal:  J Am Coll Cardiol       Date:  2005-01-04       Impact factor: 24.094

5.  Relation of multiple inflammatory biomarkers to incident atrial fibrillation.

Authors:  Renate B Schnabel; Martin G Larson; Jennifer F Yamamoto; Sekar Kathiresan; Jian Rong; Daniel Levy; John F Keaney; Thomas J Wang; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am J Cardiol       Date:  2009-05-04       Impact factor: 2.778

6.  N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.

Authors:  Kristen K Patton; Patrick T Ellinor; Susan R Heckbert; Robert H Christenson; Christopher DeFilippi; John S Gottdiener; Richard A Kronmal
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

7.  Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently.

Authors:  Mark A Crandall; Benjamin D Horne; John D Day; Jeffrey L Anderson; Joseph B Muhlestein; Brian G Crandall; J Peter Weiss; Donald L Lappé; T Jared Bunch
Journal:  Pacing Clin Electrophysiol       Date:  2009-05       Impact factor: 1.976

8.  C-reactive protein and atrial fibrillation in idiopathic dilated cardiomyopathy.

Authors:  Shimo Dai; Shu Zhang; Ying hua Guo; Jianmin Chu; Wei Hua; Fang zheng Wang
Journal:  Clin Cardiol       Date:  2009-09       Impact factor: 2.882

9.  Head-to-head comparison of B-type natriuretic peptide (BNP) and NT-proBNP in daily clinical practice.

Authors:  Johannes Mair; Falkensammer Gerda; Hiemetzberger Renate; Hanno Ulmer; Griesmacher Andrea; Otmar Pachinger
Journal:  Int J Cardiol       Date:  2007-03-13       Impact factor: 4.164

10.  Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study.

Authors:  Renate B Schnabel; Lisa M Sullivan; Daniel Levy; Michael J Pencina; Joseph M Massaro; Ralph B D'Agostino; Christopher Newton-Cheh; Jennifer F Yamamoto; Jared W Magnani; Thomas M Tadros; William B Kannel; Thomas J Wang; Patrick T Ellinor; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

View more
  66 in total

1.  Right Ventricular Structure and Function Are Associated With Incident Atrial Fibrillation: MESA-RV Study (Multi-Ethnic Study of Atherosclerosis-Right Ventricle).

Authors:  Neal A Chatterjee; Ravi V Shah; Venkatesh L Murthy; Amy Praestgaard; Sanjiv J Shah; Corey E Ventetuolo; R Graham Barr; Richard Kronmal; Joao A C Lima; David A Bluemke; Michael Jerosch-Herold; Alvaro Alonso; Steven M Kawut
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-01

Review 2.  Expert opinion paper on atrial fibrillation detection after ischemic stroke.

Authors:  Karl Georg Haeusler; Klaus Gröschel; Martin Köhrmann; Stefan D Anker; Johannes Brachmann; Michael Böhm; Hans-Christoph Diener; Wolfram Doehner; Matthias Endres; Christian Gerloff; Hagen B Huttner; Manfred Kaps; Paulus Kirchhof; Darius Günther Nabavi; Christian H Nolte; Waltraud Pfeilschifter; Burkert Pieske; Sven Poli; Wolf Rüdiger Schäbitz; Götz Thomalla; Roland Veltkamp; Thorsten Steiner; Ulrich Laufs; Joachim Röther; Rolf Wachter; Renate Schnabel
Journal:  Clin Res Cardiol       Date:  2018-04-27       Impact factor: 5.460

Review 3.  Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke.

Authors:  Shadi Yaghi; Hooman Kamel; Mitchell S V Elkind
Journal:  Neurology       Date:  2015-07-17       Impact factor: 9.910

4.  Evaluation of Risk Prediction Models of Atrial Fibrillation (from the Multi-Ethnic Study of Atherosclerosis [MESA]).

Authors:  Joshua D Bundy; Susan R Heckbert; Lin Y Chen; Donald M Lloyd-Jones; Philip Greenland
Journal:  Am J Cardiol       Date:  2019-10-10       Impact factor: 2.778

Review 5.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

6.  Preoperative levels of natriuretic peptides and the incidence of postoperative atrial fibrillation after noncardiac surgery: a prospective cohort study.

Authors:  Wojciech Szczeklik; Yannick LeManach; Jakub Fronczek; Kamil Polok; David Conen; Finlay A McAlister; Sadeesh Srinathan; Pablo Alonso-Coello; Bruce Biccard; Emmanuelle Duceppe; Diane Heels-Ansdell; Jacek Górka; Shirley Pettit; Pavel S Roshanov; P J Devereaux
Journal:  CMAJ       Date:  2020-12-07       Impact factor: 8.262

7.  The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Tsz Him Hui; Robyn L McClelland; Matthew A Allison; Carlos J Rodriguez; Richard A Kronmal; Susan R Heckbert; Erin D Michos; Philip J Barter; Kerry-Anne Rye; Kwok Leung Ong
Journal:  Atherosclerosis       Date:  2017-12-25       Impact factor: 5.162

8.  High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Kristian B Filion; Sunil K Agarwal; Christie M Ballantyne; Maria Eberg; Ron C Hoogeveen; Rachel R Huxley; Laura R Loehr; Vijay Nambi; Elsayed Z Soliman; Alvaro Alonso
Journal:  Am Heart J       Date:  2014-10-22       Impact factor: 4.749

9.  Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.

Authors:  Renate B Schnabel; Renke Maas; Na Wang; Xiaoyan Yin; Martin G Larson; Daniel Levy; Patrick T Ellinor; Steven A Lubitz; David D McManus; Jared W Magnani; Dorothee Atzler; Rainer H Böger; Edzard Schwedhelm; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am Heart J       Date:  2016-03-17       Impact factor: 4.749

10.  Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism.

Authors:  A R Folsom; P L Lutsey; S R Heckbert; K Poudel; S Basu; R C Hoogeveen; M Cushman; C M Ballantyne
Journal:  J Thromb Haemost       Date:  2018-08-11       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.